AdAlta’s BZDS1901 Manufacturing Transfer May Accelerate by Six Months

A Milestone in CAR-T Therapy Collaboration

AdAlta Limited’s subsidiary, AdCella Pty Ltd, has taken a significant step forward in the development of its first-in-class CAR-T therapy, BZDS1901, by completing the inaugural Joint Development Committee (JDC) meeting with Shanghai Cell Therapy Group (SHcell). This meeting marks the transition from independent planning to a coordinated, joint execution phase, signalling a new chapter in the partnership aimed at tackling advanced mesothelioma, a cancer with limited treatment options.

Accelerating Manufacturing and Regulatory Pathways

One of the standout outcomes from the JDC meeting is the potential to accelerate the transfer of manufacturing technology to Australia by up to six months. This advancement not only brings forward a critical development milestone but also mitigates risks associated with clinical timelines and regulatory approvals. By establishing manufacturing capabilities earlier in Australia, AdCella can optimise processes in-house and conduct toxicology studies using the exact manufacturing methods intended for clinical trials, enhancing regulatory confidence.

Complementing this, the partners have devised a two-stage engagement strategy with the US Food and Drug Administration (FDA). The initial meeting will clarify requirements for the Investigational New Drug (IND) application, while a subsequent meeting post-technology transfer will allow AdCella to present real comparability data rather than theoretical assessments. This approach is designed to reduce regulatory uncertainty and improve the quality of feedback, smoothing the path toward clinical trial commencement.

Clinical Progress and Strategic Flexibility

Meanwhile, the China Investigator Initiated Trial (IIT) for BZDS1901 has completed dosing in its first extension cohort involving five mesothelioma patients, with updated clinical results pending. The JDC meeting also identified opportunities to refine clinical trial strategies for both the ongoing China IIT and the planned Phase 1 trial in Australia, underscoring the dynamic nature of the collaboration.

Importantly, the existing collaboration agreement between AdCella and SHcell is sufficiently flexible to accommodate changes in manufacturing timelines and regulatory strategies, as well as AdCella’s current resourcing plans. This adaptability is crucial in the fast-evolving biotechnology landscape, allowing the partnership to respond effectively to new data and regulatory feedback.

Positioning for the Future

AdAlta’s broader strategy leverages Asia’s strengths in T cell therapy innovation alongside Australia’s clinical and manufacturing expertise, aiming to bridge Eastern innovation with Western regulatory markets. BZDS1901, with its novel immune checkpoint inhibitor armouring and rapid manufacturing process, represents a promising candidate in the underserved solid tumour immunotherapy space, projected to grow substantially in the coming years.

As AdAlta and AdCella advance this collaboration, investors and observers will be watching closely for the forthcoming clinical data updates and the progress of regulatory engagements, which will be pivotal in validating the accelerated development pathway and the therapy’s potential impact.